Children, Infants & Newborns

Parents or caregivers of a child with ADHD ages 6, 7 or 8 are invited to participate in a study to reduce ADHD symptoms. Parents are asked to complete surveys at two or three time points and to complete a six-week online course called the Nurtured Heart Approach.

Primary disease category: 
Secondary disease category(ies): 

The Oral Bacterial Extract (ORBEX) Study is a three year study to see whether the wheezing and lower respiratory tract illnesses that lead to asthma can be prevented. The goal is to find if a medication that is used in Europe, called Broncho-Vaxom®, can prevent wheezing lower respiratory infections in young children. It may work to stimulate a child’s immune system in order to increase the body’s defenses against germs that cause children to have respiratory illnesses.

Primary disease category: 
Secondary disease category(ies): 

We are looking for families with a child or adolescent with a diagnosis of type 1 diabetes to participate in a study examining the effects of an intervention to assist families with their daily routines. Assessments and the intervention consultation address sleep, school, and family activities that may help or interfere with diabetes management.

Primary disease category: 
Secondary disease category(ies): 

We plan to study a cohort of children with central lines placed to determine who is at high risk for thrombotic event.

Primary disease category: 

This study will consist of a brief survey (approximately 5 min) examining the family history and behaviors of mothers who have previously given birth. Our goal is to examine birth outcomes to improve maternal-child health. You will receive a children's book for your participation.

Primary disease category: 
Secondary disease category(ies): 

Do you have a daughter between the ages of 9 and 11 years of age? Researchers at the University of Arizona are conducting a HPV vaccine study that may interest you! HPV is short for human papillomavirus, a common virus. HPV vaccines are usually given as a series of three injections over 6 months to protect against HPV-related cancers and diseases. This new HPV vaccine study is recruiting 9-11 year-old girls to determine if one injection of the HPV vaccine will produce long-term immune response.

Primary disease category: 

The Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE) study is designed as a multi-center international observational, cross sectional study of new cases of PARDS involving 5 continuous days of screening and patient enrollment, occurring every 2 months for a year (6 total study weeks). Included patients will have a new diagnosis of PARDS during the study week or be at risk for PARDS. Data collection will concentrate on the first 3 days of PARDS diagnosis, and follow outcomes such as mortality and length of ventilation.

Primary disease category: 
Secondary disease category(ies): 

Optimal delivery of nutritional support during critical illness is central to appropriate intensive care unit management, and yet fundamental gaps in knowledge exist regarding timing, route, dose, and type of nutritional support for critically ill infants and children. Understanding how to optimize nutritional support during pediatric critical illness is important because even brief periods of malnutrition in infancy result in permanent negative effects on long-term neurocognitive development.

Primary disease category: 
Secondary disease category(ies): 

Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to be able to develop into the various cell types that make up the human body. Skin biopsies taken from pediatric patients with rare neurodegenerative disorders and age matched controls will be used to generate patient specific iPSC cell lines. These cell lines will then be developed into various neuronal cell populations in order to study the genetic cause of these rare and incurable diseases.

Primary disease category: 

Primary Aims
1.1.1 To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone.
1.2 Secondary Aims
1.2.1 To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy

Primary disease category: 
Secondary disease category(ies): 

Pages

Subscribe to RSS - Children, Infants & Newborns